PAI
CAPR icon

Palo Alto Investors’s Capricor Therapeutics CAPR Stock Holding History

Palo Alto Investors’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.98M Buy
229,763
+3,459
+2% +$92.2K 1.07% 25
2025
Q4 		$6.53M Buy
+226,304
New +$2.96M 0.91% 24

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Palo Alto Investors's CAPR Position: Q1 2026 in Review

Palo Alto Investors increased its Capricor Therapeutics (CAPR) stake by 1.5% in Q1 2026, buying an estimated $92.2K and bringing the position to 229,763 shares worth $6.98M. The position accounts for 1.07% of the portfolio, ranked #25.

Palo Alto Investors first reported a position in CAPR in Q4 2025 and has held it in 2 quarters since. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Palo Alto Investors held 229,763 shares of Capricor Therapeutics worth $6.98M as of Q1 2026.
  • Palo Alto Investors bought 3,459 Capricor Therapeutics shares in Q1 2026, an estimated $92.2K.
  • Capricor Therapeutics made up 1.07% of Palo Alto Investors's portfolio in Q1 2026, its #25 holding.
  • Palo Alto Investors first reported a position in Capricor Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Palo Alto Investors's 13F filing for Q1 2026, filed 15 May 2026.